Concordantly, several authors reported that despite the fact that IHC is currently used for human breast cancer erbB-2 protein categorisation, the application of different, common, commercially available erbB-2 antibodies produces variability in the IHC results [65]–[69]. Here, ERBB2 is linked to breast carcinoma.